Anti-TNF-Alpha Therapy and Systemic Vasculitis

Table 1

Randomized controlled trials performed in GCA.

References	Design/anti-TNF-α therapy	Number of patients	Main objectives	Follow-up	Main results	Side effects
Hoffman et al. [21]	Randomized controlled trial IFX versus placebo	44 (28 IFX, 16 placebo)	Free of relapses and adverse events at 54 weeks	54 weeks	Stopped early at week 22 for lack of efficacy (43% for IFX versus 50% for placebo)	Infection: 71% for IFX versus 56% for placebo (NS)
Martínez-Taboada et al. [22]	Randomized controlled trial ETN versus placebo	17 (8 ETN, 9 placebo)	To withdraw the corticosteroid therapy at 12 months	12 months	50% for ETN versus 22% for placebo (NS)	No differences between the two groups
Mariette et al. [23]	Randomized controlled trial ADA versus placebo	70 (34 ADA, 36 placebo)	Remission and corticosteroid < 0,1 mg/kg/day at 26 weeks	26 weeks	55,9% for ADA 50% for placebo (NS)	Severe infections: 8,8% for ADA versus 13,9% for placebo (NS)

ns: nonsignificant.